Park Ha Biological Technology Co., Ltd. announced the successful passage of all resolutions at its Extraordinary General Meeting and Class A Meeting held on July 13, 2026. Shareholders approved increasing the company's authorized share capital from US$3,000,000 to US$300,000,000 by creating 297,000,000,000 additional ordinary shares. The Board was authorized to execute share consolidations (2-for-1 to 5,000-for-1) and subdivisions (2-for-1 to 100-for-1) over the next three years. Additionally, a special resolution was passed to increase the voting rights of Class B Ordinary Shares from 20 votes to 100 votes per share. The company operates in the biotechnology industry.

Park Ha Biological Technology Co., Ltd. filed a membership application with the Personal Care Products Council on July 1, 2026, to establish a compliance framework for the North American market and facilitate its entry into Amazon's North America marketplace. The application is currently under review. The company operates in the personal care and biological technology industry, providing products for the cosmetics and skincare industry.

Park Ha Biological Technology Co., Ltd. announced on June 29, 2026, that it is initiating cooperation with Amazon and preparing for entry into the North American personal care market. The company is currently advancing four workstreams: store qualification registration, Amazon brand registration, compliance framework establishment, and localized product operation strategies. Park Ha Biological Technology Co., Ltd. operates in the personal care and skincare products industry and develops scientifically formulated skincare products.

Park Ha Biological Technology Co., Ltd. entered into a strategic partnership with Cloud Factory Technology Holdings Limited (02512.HK) on June 23, 2026, to develop an AI-driven ecosystem for the beauty industry. The collaboration focuses on organizational efficiency, store space optimization, and AI-powered supply chain and inventory management. Park Ha Biological Technology Co., Ltd. operates in the biotechnology and beauty industry sector.

Park Ha Biological Technology Co., Ltd. closed a best-efforts offering of 1,133,332 Class A ordinary shares and 200,000 pre-funded warrants at $1.50 per unit. The offering, which closed on June 15, 2026, generated approximately $2.0 million in gross proceeds for working capital and general corporate purposes. Park Ha Biological Technology Co., Ltd. is a biotechnology company based in China.

On June 12, 2026, Park Ha Biological Technology Co., Ltd. announced the pricing of a registered direct offering. The filing serves as a notice of the pricing event via a press release. The company operates in the biotechnology industry, focusing on biological technology development.